221 related articles for article (PubMed ID: 14643298)
1. Drug transport and drug resistance in African trypanosomes.
Mäser P; Lüscher A; Kaminsky R
Drug Resist Updat; 2003 Oct; 6(5):281-90. PubMed ID: 14643298
[TBL] [Abstract][Full Text] [Related]
2. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review).
Gehrig S; Efferth T
Int J Mol Med; 2008 Oct; 22(4):411-9. PubMed ID: 18813846
[TBL] [Abstract][Full Text] [Related]
3. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate.
Maina N; Maina KJ; Mäser P; Brun R
Acta Trop; 2007; 104(2-3):84-90. PubMed ID: 17765860
[TBL] [Abstract][Full Text] [Related]
4. Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol.
Graf FE; Ludin P; Wenzler T; Kaiser M; Brun R; Pyana PP; Büscher P; de Koning HP; Horn D; Mäser P
PLoS Negl Trop Dis; 2013; 7(10):e2475. PubMed ID: 24130910
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic strategies against Trypanosoma brucei: drug targets vs. drug targeting.
Lüscher A; de Koning HP; Mäser P
Curr Pharm Des; 2007; 13(6):555-67. PubMed ID: 17346174
[TBL] [Abstract][Full Text] [Related]
6. Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter.
Gilbert IH
Parasitology; 2014 Jan; 141(1):28-36. PubMed ID: 23931634
[TBL] [Abstract][Full Text] [Related]
7. The human trypanolytic factor: a drug shaped naturally.
Vanhamme L
Infect Disord Drug Targets; 2010 Aug; 10(4):266-82. PubMed ID: 20429865
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.
Wenzler T; Yang S; Braissant O; Boykin DW; Brun R; Wang MZ
Antimicrob Agents Chemother; 2013 Nov; 57(11):5330-43. PubMed ID: 23959303
[TBL] [Abstract][Full Text] [Related]
9. Veterinary link to drug resistance in human African trypanosomiasis?
Barrett MP
Lancet; 2001 Aug; 358(9282):603-4. PubMed ID: 11530144
[No Abstract] [Full Text] [Related]
10. Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.
Pyana Pati P; Van Reet N; Mumba Ngoyi D; Ngay Lukusa I; Karhemere Bin Shamamba S; Büscher P
PLoS Negl Trop Dis; 2014 Oct; 8(10):e3212. PubMed ID: 25275572
[TBL] [Abstract][Full Text] [Related]
11. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.
Nok AJ
Parasitol Res; 2003 May; 90(1):71-9. PubMed ID: 12743807
[TBL] [Abstract][Full Text] [Related]
12. The phenomenon of treatment failures in Human African Trypanosomiasis.
Brun R; Schumacher R; Schmid C; Kunz C; Burri C
Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of human African trypanosomiasis.
Burchmore RJ; Ogbunude PO; Enanga B; Barrett MP
Curr Pharm Des; 2002; 8(4):256-67. PubMed ID: 11860365
[TBL] [Abstract][Full Text] [Related]
14. Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes.
de Koning HP
Trends Parasitol; 2008 Aug; 24(8):345-9. PubMed ID: 18599351
[TBL] [Abstract][Full Text] [Related]
15. New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
Wenzler T; Boykin DW; Ismail MA; Hall JE; Tidwell RR; Brun R
Antimicrob Agents Chemother; 2009 Oct; 53(10):4185-92. PubMed ID: 19620327
[TBL] [Abstract][Full Text] [Related]
16. Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense.
Graf FE; Ludin P; Arquint C; Schmidt RS; Schaub N; Kunz Renggli C; Munday JC; Krezdorn J; Baker N; Horn D; Balmer O; Caccone A; de Koning HP; Mäser P
Cell Mol Life Sci; 2016 Sep; 73(17):3387-400. PubMed ID: 26973180
[TBL] [Abstract][Full Text] [Related]
17. Diamidines for human African trypanosomiasis.
Paine MF; Wang MZ; Generaux CN; Boykin DW; Wilson WD; De Koning HP; Olson CA; Pohlig G; Burri C; Brun R; Murilla GA; Thuita JK; Barrett MP; Tidwell RR
Curr Opin Investig Drugs; 2010 Aug; 11(8):876-83. PubMed ID: 20721830
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness.
Wenzler T; Yang S; Patrick DA; Braissant O; Ismail MA; Tidwell RR; Boykin DW; Wang MZ; Brun R
Antimicrob Agents Chemother; 2014 Aug; 58(8):4452-63. PubMed ID: 24867978
[TBL] [Abstract][Full Text] [Related]
19. Aquaglyceroporin-null trypanosomes display glycerol transport defects and respiratory-inhibitor sensitivity.
Jeacock L; Baker N; Wiedemar N; Mäser P; Horn D
PLoS Pathog; 2017 Mar; 13(3):e1006307. PubMed ID: 28358927
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationships of new quinolone-type molecules against Trypanosoma brucei.
Hiltensperger G; Jones NG; Niedermeier S; Stich A; Kaiser M; Jung J; Puhl S; Damme A; Braunschweig H; Meinel L; Engstler M; Holzgrabe U
J Med Chem; 2012 Mar; 55(6):2538-48. PubMed ID: 22376072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
